Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|December 27, 2007
HIV-associated lipodystrophy syndrome: A review of clinical aspectsJean-Guy Baril, Patrice Junod, Roger Leblanc, et al.
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|October 17, 2008
Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionalsPierre Côté, Jean-Guy Baril, Marie-Nicole Hébert, et al.
Viruses|August 28, 2021
The Role of Phylogenetics in Unravelling Patterns of HIV Transmission towards Epidemic Control: The Quebec Experience (2002-2020)Bluma G Brenner, Ruxandra-Ilinca Ibanescu, Nathan Osman, et al.
Frontiers in Immunology|March 9, 2019
CXCL13 as a Biomarker of Immune Activation During Early and Chronic HIV InfectionVikram Mehraj, Rayoun Ramendra, Stéphane Isnard, et al.
Patient Preference and Adherence|December 20, 2022
Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286)Marina B Klein, Jim Young, David Ortiz-Paredes, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|December 1, 2025
Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 updateDarrell H S Tan, Mark W Hull, Stanley O Onyegbule, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 25, 2020
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled AnalysisJoseph Eron, Chien-Ching Hung, Jean-Guy Baril, et al.
Open Forum Infectious Diseases|November 18, 2020
Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World DataMohamed N'dongo Sangaré, Jean-Guy Baril, Alexandra de Pokomandy, et al.
HIV Clinical Trials|October 25, 2007
Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimenMona R Loutfy, Nabil Ackad, Tony Antoniou, et al.
BMC Infectious Diseases|September 13, 2017
The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocolMadeleine Durand, Carl Chartrand-Lefebvre, Jean-Guy Baril, et al.
Pageof 7